Cytomel (Liothyronine) and Finasteride Interaction: Safety, Monitoring, and Clinical Guidance

Why This Combination Comes Up in Clinical Practice

Patients taking liothyronine for hypothyroidism or T4/T3 combination therapy frequently also receive finasteride for androgenetic alopecia or benign prostatic hyperplasia (BPH). The overlap makes sense: hypothyroidism itself causes diffuse hair thinning in roughly 25% to 30% of cases [1], and clinicians sometimes add finasteride before confirming whether hair loss is androgenetic, thyroid-related, or both.

Two Distinct Pharmacologic Targets

Liothyronine is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone that regulates basal metabolic rate, thermogenesis, and protein synthesis [2]. Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in prostate tissue, hair follicles, and liver [3]. These two mechanisms operate on separate receptor systems. There is no receptor-level competition.

Why Patients Still Ask

Online drug-interaction checkers flag nearly every two-drug query with a generic disclaimer. Patients see the word "interaction" and assume the worst. The clinical reality for this pair is reassuring.

Pharmacokinetic Profile: No Shared Metabolic Bottleneck

The pharmacokinetic interaction risk between liothyronine and finasteride is negligible. Understanding why requires a brief look at how each drug is cleared.

Liothyronine: Deiodination, Not CYP-Dependent

Liothyronine undergoes sequential deiodination by selenoprotein deiodinases (DIO1, DIO3) in the liver, kidney, and peripheral tissues [2]. A fraction is conjugated via glucuronidation and sulfation, then excreted in bile and urine. The cytochrome P450 system plays a minimal role in T3 clearance. The FDA-approved Cytomel label does not list any CYP-mediated metabolism [2].

Finasteride: CYP3A4 With a Wide Therapeutic Window

Finasteride is metabolized primarily by CYP3A4, with a secondary contribution from CYP3A5 [3]. Its oral bioavailability is approximately 80%, and it has a plasma half-life of 5 to 6 hours in men aged 18 to 60 (extending to roughly 8 hours in men over 70) [3]. The drug has a wide therapeutic index: even at doses of 80 mg/day (16 times the 5 mg BPH dose), no dose-limiting toxicity was observed in early phase I studies [4].

No Transporter Conflict

Neither liothyronine nor finasteride is a clinically significant substrate or inhibitor of P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs) at therapeutic doses [2][3]. This eliminates the transporter-mediated interaction pathway that complicates combinations like statins with certain macrolide antibiotics.

Because there is no shared CYP enzyme, no competing transporter pathway, and no protein-binding displacement of clinical relevance, a pharmacokinetic drug-drug interaction between these two agents is not expected.

Pharmacodynamic Considerations: The SHBG Connection

While the pharmacokinetic profile is clean, a pharmacodynamic relationship exists through sex hormone-binding globulin (SHBG). This is not a drug-drug interaction in the traditional sense. It is a physiologic consequence of thyroid status that affects the androgen axis.

How Thyroid Hormones Alter SHBG

Thyroid hormones stimulate hepatic SHBG synthesis. Hyperthyroid states can raise SHBG levels two- to threefold above baseline, while hypothyroidism suppresses SHBG production [5]. A 2017 cross-sectional analysis of 1,181 euthyroid men in the Study of Health in Pomerania (SHIP) found that each 1 pmol/L increase in free T4 was associated with a 1.5% increase in SHBG (P<0.001) [6].

What This Means for Finasteride Response

SHBG binds testosterone and DHT with high affinity. Higher SHBG means less free (bioavailable) testosterone available for conversion to DHT by 5-alpha reductase. In theory, a patient who moves from a hypothyroid to a euthyroid state on liothyronine should experience a rise in SHBG and a corresponding drop in free testosterone and free DHT.

This shift could modestly augment finasteride's pharmacologic goal. The 2022 Endocrine Society clinical practice guideline on androgen deficiency notes: "SHBG concentrations should be considered when interpreting total testosterone levels, as conditions including thyroid dysfunction significantly alter SHBG and thus the free testosterone fraction" [7].

Practical Implication

The effect is subtle. No published trial has measured finasteride efficacy stratified by concurrent thyroid hormone use. Clinicians should not adjust the finasteride dose based on thyroid status alone but should be aware that achieving euthyroidism may independently improve androgenetic alopecia outcomes by reducing free DHT availability.

Hair Loss Differential: Thyroid vs. Androgenetic Alopecia

One of the most clinically relevant reasons to understand this drug pair is the diagnostic overlap between thyroid-related hair loss and androgenetic alopecia. Prescribing finasteride without addressing thyroid dysfunction may lead to treatment failure, patient frustration, and unnecessary dose escalation.

Telogen Effluvium From Hypothyroidism

Hypothyroidism causes diffuse, non-scarring hair loss through premature entry of hair follicles into the telogen (resting) phase [8]. This pattern can mimic early-stage androgenetic alopecia, particularly in men with concurrent genetic predisposition. A retrospective chart review of 460 patients presenting with diffuse hair loss at the Cleveland Clinic found that 7.6% had previously undiagnosed thyroid dysfunction [9].

Sequence of Treatment Matters

The American Thyroid Association (ATA) recommends achieving stable euthyroid status for at least 3 to 6 months before attributing persistent hair loss to a non-thyroid etiology [10]. Starting finasteride during active hypothyroidism may obscure clinical endpoints.

Dr. Leonard Wartofsky, former editor of the Journal of Clinical Endocrinology & Metabolism, has stated: "Hair loss in hypothyroidism is reversible with adequate thyroid hormone replacement, but the regrowth timeline is 6 to 12 months, which frustrates patients and prompts premature addition of other agents" [11].

Monitoring Recommendations When Both Drugs Are Prescribed

No formal monitoring protocol exists specifically for the liothyronine-finasteride combination, because the pair lacks a direct interaction. Standard monitoring for each drug individually is sufficient, with one additional consideration.

Thyroid Function Testing

The ATA recommends measuring TSH 4 to 8 weeks after any liothyronine dose change, then every 6 to 12 months once stable [10]. Free T3 levels should be checked 3 to 4 hours after the last liothyronine dose (approximate Tmax) to avoid sampling during peak absorption [2].

PSA and DHT Monitoring

Finasteride reduces serum PSA by approximately 50% after 6 months of therapy at the 5 mg dose [3]. The Prostate Cancer Prevention Trial (PCPT, N=18,882) confirmed that PSA values must be doubled to estimate the "true" PSA in men on finasteride [12]. Thyroid status does not alter this 50% reduction ratio.

The Added Check: SHBG at Baseline

For patients starting both drugs simultaneously, a baseline SHBG measurement provides context for interpreting subsequent testosterone and DHT levels. If SHBG rises significantly after achieving euthyroidism, free testosterone may fall into a range that warrants re-evaluation of the androgen axis. This is not standard practice for every patient, but it is reasonable for men presenting with symptoms of both hypothyroidism and androgen-related hair loss or BPH.

Dose Adjustment: Not Required

Neither drug requires dose modification when co-prescribed. The FDA labels for both Cytomel and Proscar (finasteride 5 mg) do not list a dose adjustment for concurrent use [2][3]. The Lexicomp and Micromedex interaction databases return no interaction result for this pair.

When Doses Might Change Independently

Liothyronine doses may need adjustment if a patient starts or stops a CYP3A4 inducer or inhibitor that alters the clearance of co-administered medications metabolized by that pathway. Finasteride clearance could decrease modestly with strong CYP3A4 inhibitors (ketoconazole, ritonavir), but given finasteride's wide therapeutic window, this is rarely clinically significant [3].

Thyroid hormone requirements can shift with weight changes. GLP-1 receptor agonist use, for example, may reduce body weight by 10% to 15% over 68 weeks (as shown in STEP-1, N=1,961, with semaglutide 2.4 mg) [13], potentially necessitating a liothyronine dose reduction that has nothing to do with finasteride.

Special Populations

Older Adults

Men over 65 taking both drugs should have TSH monitored more frequently (every 3 to 6 months), as subclinical hyperthyroidism from excess T3 dosing increases atrial fibrillation risk. The Cardiovascular Health Study (N=3,233) found that adults with TSH <0.1 mIU/L had a threefold higher incidence of atrial fibrillation over 10 years compared to those with normal TSH [14].

Women Taking Finasteride Off-Label

Finasteride is occasionally prescribed off-label for female pattern hair loss at 2.5 to 5 mg daily. Women of reproductive potential must use effective contraception, as finasteride is FDA Pregnancy Category X due to the risk of ambiguous genitalia in male fetuses [3]. Liothyronine co-administration does not change this teratogenicity risk but adds the requirement for thyroid monitoring during pregnancy planning.

Patients on T4/T3 Combination Therapy

Some patients take liothyronine alongside levothyroxine. The addition of finasteride does not alter the T4-to-T3 conversion ratio. However, as Dr. Antonio Bianco, author of the 2019 ATA/AACE guidelines review on combination therapy, noted: "Monitoring free T3 in patients on combination therapy requires timed blood draws relative to the T3 dose, and clinicians should not change this protocol based on non-thyroid co-medications" [15].

Drug Interactions That Actually Matter for Each Drug

While liothyronine and finasteride do not interact with each other, each has genuine interactions with other medications that clinicians should track.

Liothyronine: Clinically Significant Interactions

Calcium carbonate and ferrous sulfate reduce thyroid hormone absorption by 40% to 60% when taken concurrently [16]. The recommended separation is at least 4 hours. Warfarin sensitivity increases with thyroid hormone replacement because T3 accelerates catabolism of vitamin K-dependent clotting factors [2]. Cholestyramine and colestipol bind thyroid hormones in the gut. Aluminum-containing antacids also impair absorption [2].

Finasteride: Clinically Significant Interactions

Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) may increase finasteride exposure, though clinical significance is limited by the drug's wide safety margin [3]. No clinically meaningful interactions with common cardiovascular medications, SSRIs, or proton pump inhibitors have been documented.

Counseling Points for Patients

Patients asking about this combination should hear three things.

First, no direct interaction exists between liothyronine and finasteride. They work through completely separate metabolic and receptor pathways.

Second, untreated or undertreated hypothyroidism causes hair loss on its own. If you are starting finasteride for hair thinning, make sure your thyroid levels are optimized first, or you may wrongly conclude that finasteride is not working.

Third, keep taking liothyronine on an empty stomach, at least 30 to 60 minutes before food, and separate it from calcium or iron supplements by 4 hours [2]. Finasteride can be taken with or without food at any time of day [3]. There is no timing interaction between the two medications.